Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 0.40% is 120% above its 5-year average of -2.04%, around the middle of its 5-year range (-17.44%–28.74%).
230.01% above its 12-month average of 0.12%.
Reported quarterly EBITDA margin; no daily interpolation. Q1 FY2027 (2026-07-31): -0.62%.
EBITDA MARGIN
0.40%
EBITDA MARGIN AVG TTM
0.12%
EBITDA MARGIN AVG 3Y
-2.89%
EBITDA MARGIN AVG 5Y
-2.04%
EBITDA MARGIN AVG 10Y
-1.42%
EBITDA MARGIN AVG 15Y
-29.56%
EBITDA MARGIN AVG 20Y
-34.94%
CURRENT VS TTM AVG
+230.01%
CURRENT VS 3Y AVG
+113.86%
CURRENT VS 5Y AVG
+119.63%
CURRENT VS 10Y AVG
+128.17%
CURRENT VS 15Y AVG
+101.35%
CURRENT VS 20Y AVG
+101.14%
Champions Oncology, Inc.
Market Cap
$69.61M
EBITDA Margin
0.40%
TTM Avg
0.12%
3Y Avg
-2.89%
5Y Avg
-2.04%
Market Cap
$68.90M
EBITDA Margin
-0.04%
TTM Avg
-76.47%
3Y Avg
-54.24%
5Y Avg
-650.20%
Market Cap
$70.63M
EBITDA Margin
-8394.83%
TTM Avg
-8394.83%
3Y Avg
-4949.66%
5Y Avg
-3042.42%
Market Cap
$68.10M
EBITDA Margin
-103.63%
TTM Avg
-143.63%
3Y Avg
-176.25%
5Y Avg
-194.05%
Market Cap
$71.23M
EBITDA Margin
-40176.79%
TTM Avg
-26409.54%
3Y Avg
-18300.96%
5Y Avg
-13878.09%
Market Cap
$67.52M
EBITDA Margin
-34495.00%
TTM Avg
-19432.00%
3Y Avg
-15233.78%
5Y Avg
-9657.34%
Market Cap
$72.32M
EBITDA Margin
-31.36%
TTM Avg
-442.92%
3Y Avg
-595.18%
5Y Avg
-526.87%
Market Cap
$72.83M
EBITDA Margin
-85.70%
TTM Avg
-57.28%
3Y Avg
-59.72%
5Y Avg
-51.35%
Market Cap
$73.27M
EBITDA Margin
-257.20%
TTM Avg
-292.35%
3Y Avg
-520.13%
5Y Avg
-2376.66%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Champions Oncology, Inc. (CSBR) | $69.61M | 0.40% | 0.12% | -2.89% | -2.04% |
| Spero Therapeutics, Inc. (SPRO)vs › | $68.90M | -0.04% | -76.47% | -54.24% | -650.20% |
| Tiziana Life Sciences Ltd (TLSA)vs › | $70.63M | -8394.83% | -8394.83% | -4949.66% | -3042.42% |
| Fortress Biotech, Inc. (FBIO)vs › | $68.10M | -103.63% | -143.63% | -176.25% | -194.05% |
| Gain Therapeutics, Inc. (GANX)vs › | $71.23M | -40176.79% | -26409.54% | -18300.96% | -13878.09% |
| iBio, Inc. (IBIO)vs › | $67.52M | -34495.00% | -19432.00% | -15233.78% | -9657.34% |
| Verrica Pharmaceuticals Inc. (VRCA)vs › | $72.32M | -31.36% | -442.92% | -595.18% | -526.87% |
| MindWalk Holdings Corp. (HYFT)vs › | $72.83M | -85.70% | -57.28% | -59.72% | -51.35% |
| Hyperfine, Inc. (HYPR)vs › | $73.27M | -257.20% | -292.35% | -520.13% | -2376.66% |
| Gossamer Bio, Inc. (GOSS)vs › | $65.87M | -334.74% | -191.68% | -191.68% | -191.68% |
Gross Margin
49.3%
EBITDA Margin
0.4%
Operating Margin
-1.7%
Net Margin
-1.9%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-07-31 | -0.62% |
| 2026-04-30 | -2.24% |
| 2026-01-31 | 0.93% |
| 2025-10-31 | 3.60% |
| 2025-07-31 | -1.06% |
| 2025-04-30 | -10.68% |
| 2025-01-31 | 28.74% |
| 2024-10-31 | 8.38% |
| 2024-07-31 | 12.64% |
| 2024-04-30 | 1.33% |
| 2024-01-31 | -17.44% |
| 2023-10-31 | -12.71% |
| 2023-07-31 | -16.77% |
| 2023-04-30 | -14.83% |
| 2023-01-31 | -14.74% |
| 2022-10-31 | 3.97% |
| 2022-07-31 | 1.78% |
| 2022-04-30 | 2.00% |
| 2022-01-31 | 9.29% |
| 2021-10-31 | 5.17% |
| 2021-07-31 | 1.26% |
| 2021-04-30 | -1.19% |
| 2021-01-31 | 11.83% |
| 2020-10-31 | 3.10% |
| 2020-07-31 | 3.15% |
| 2020-04-30 | -19.04% |
| 2020-01-31 | 7.23% |
| 2019-10-31 | 6.15% |
| 2019-07-31 | -6.41% |
| 2019-04-30 | 0.74% |
| 2019-01-31 | -3.20% |
| 2018-10-31 | 6.36% |
| 2018-07-31 | 9.62% |
| 2018-04-30 | -10.00% |
| 2018-01-31 | 1.06% |
| 2017-10-31 | 0.38% |
| 2017-07-31 | -11.46% |
| 2017-04-30 | -63.12% |
| 2017-01-31 | -38.18% |
| 2016-10-31 | -10.12% |
| 2016-07-31 | -67.52% |
| 2016-04-30 | -88.37% |
| 2016-01-31 | -91.50% |
| 2015-10-31 | -82.60% |
| 2015-07-31 | -101.35% |
| 2015-04-30 | -72.69% |
| 2015-01-31 | -183.87% |
| 2014-10-31 | -191.92% |
| 2014-07-31 | -192.10% |
| 2014-04-30 | -94.51% |
| 2014-01-31 | -36.64% |
| 2013-10-31 | -69.20% |
| 2013-07-31 | -23.71% |
| 2013-04-30 | -105.10% |
| 2013-01-31 | -22.97% |
| 2012-10-31 | -128.05% |
| 2012-07-31 | -73.36% |
| 2012-04-30 | -185.52% |
| 2012-01-31 | -73.33% |
| 2011-10-31 | -140.67% |
| 2011-07-31 | -133.72% |
| 2011-04-30 | -182.58% |
| 2011-01-31 | -27.66% |
| 2010-10-31 | -107.72% |
| 2010-07-31 | -37.06% |
| 2010-04-30 | -28.63% |
| 2010-01-31 | -104.58% |
| 2009-10-31 | -44.69% |
| 2009-07-31 | -103.95% |
| 2009-01-31 | -48.29% |
| 2008-10-31 | -15.26% |
| 2008-07-31 | -9.96% |
| 2008-04-30 | -173.42% |
| 2008-01-31 | 70.34% |
| 2007-07-31 | 12.02% |
| 2005-04-30 | 3.19% |
| 2005-01-31 | 17.64% |
| 2004-10-31 | -13.90% |
| 2004-07-31 | -10.21% |
| 2004-04-30 | 3.83% |
| 2004-01-31 | -9.07% |
| 2003-10-31 | -4.44% |
| 2003-07-31 | -6.49% |
| 2003-04-30 | -10.64% |
| 2003-01-31 | -6.89% |
| 2002-10-31 | 8.85% |
